NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
- Recruiting
- Dec 1, 2022
- 1 min read
Updated: Feb 4, 2024
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma
iMMagine-1
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma
A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT05396885
Official Title: A Phase II Study of CART-ddBMCA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (iMMagine-1)
First Posted: May 31, 2022
Click here to see details on ClinicalTrials.gov
Biological: CART-ddBCMA
BCMA-directed CAR T-cell therapy using d domain
Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA (Code C167337)
Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA
Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein
ARC-T Plus Anti-BCMA SparX
Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA
TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells
Locations
United States, Massachusetts
Massachusetts General Hospital
United States, Wisconsin
Medical College of Wisconsin